Naoki Isogawa Selected Research

tanezumab

9/2022	Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.
4/2022	Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.
1/2021	Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoki Isogawa Research Topics

Disease

3	Ulcerative Colitis 10/2019 - 01/2018
2	Pain (Aches) 09/2022 - 01/2021
2	Osteoarthritis 09/2022 - 01/2021
2	Herpes Zoster 10/2019 - 11/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 11/2022
1	Diabetes Mellitus 11/2022
1	Heart Failure 11/2022
1	Hypertension (High Blood Pressure) 11/2022
1	Neoplasms (Cancer) 11/2022
1	Osteonecrosis (Kienbock's Disease) 09/2022
1	Low Back Pain (Lumbago) 04/2022
1	Arthralgia (Joint Pain) 01/2021
1	Hip Osteoarthritis (Coxarthrosis) 01/2021
1	Crohn Disease (Crohn's Disease) 01/2020
1	Ulcer 01/2020
1	Infections 04/2018
1	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2017
1	Macular Edema 09/2014

Drug/Important Bio-Agent (IBA)

4	tofacitinibIBA 10/2019 - 11/2017
3	tanezumabIBA 09/2022 - 01/2021
2	Monoclonal AntibodiesIBA 09/2022 - 01/2020
2	Prostaglandins AIBA 09/2022 - 11/2017
2	Janus Kinase InhibitorsIBA 10/2019 - 04/2018
1	Immunologic Factors (Immunomodulators)IBA 11/2022
1	HDL LipoproteinsIBA 11/2022
1	Nerve Growth Factor (NGF)IBA 09/2022
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 09/2022
1	Celecoxib (Celebrex)FDA Link 04/2022
1	Analgesics (Analgesic Drugs)IBA 01/2021
1	ontamalimabIBA 01/2020
1	Cell Adhesion Molecule-1IBA 01/2020
1	C-Reactive ProteinIBA 01/2020
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	pegaptanib (Macugen)FDA Link 09/2014

Therapy/Procedure

3	Therapeutics 10/2019 - 01/2018
1	Intravitreal Injections 09/2014